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Abstract
Background: Gene expression analysis has many applications in cancer diagnosis, prognosis and therapeutic care.
Relative quantification is the most widely adopted approach whereby quantification of gene expression is
normalised relative to an endogenously expressed control (EC) gene. Central to the reliable determination of gene
expression is the choice of control gene. The purpose of this study was to evaluate a panel of candidate EC genes
from which to identify the most stably expressed gene(s) to normalise RQ-PCR data derived from primary
colorectal cancer tissue.
Results: The expression of thirteen candidate EC genes: B2M, HPRT, GAPDH, ACTB, PPIA, HCRT, SLC25A23, DTX3,
APOC4, RTDR1, KRTAP12-3, CHRNB4 and MRPL19 were analysed in a cohort of 64 colorectal tumours and tumour
associated normal specimens. CXCL12, FABP1, MUC2 and PDCD4 genes were chosen as target genes against which
a comparison of the effect of each EC gene on gene expression could be determined. Data analysis using
descriptive statistics, geNorm, NormFinder and qBasePlus indicated significant difference in variances between
candidate EC genes. We determined that two genes were required for optimal normalisation and identified B2M
and PPIA as the most stably expressed and reliable EC genes.
Conclusion: This study identified that the combination of two EC genes (B2M and PPIA) more accurately
normalised RQ-PCR data in colorectal tissue. Although these control genes might not be optimal for use in other
cancer studies, the approach described herein could serve as a template for the identification of valid ECs in other
cancer types.
Background
Colorectal cancer (CRC) is one of the most common
causes of cancer worldwide affecting almost a million
people annually and resulting in approximately 500,000
deaths [1]. Approximately 5% of individuals born today
will be diagnosed with colorectal cancer during their
lives, representing a lifetime risk of 1 in 19. CRC
remains a serious threat to life with approximately 20%
of patients presenting with late stage metastatic disease.
Although 5 year survival rates are favourable at 80-90%
for early stage disease, this drops significantly to less
than 10% with the presence of distal metastasis.
The majority of colorectal tumours originate from
adenomatous precursor lesions and develop along a
well-defined adenoma-carcinoma sequence. According
to this model the culmination of mutational events
including activation of oncogenes and loss of function
of tumour suppressor genes results in the emergence of
carcinomas [2]. Molecular profiling across the spectrum
of normal-adenoma-tumour tissue types has yielded
many candidate genes in the search for novel molecular
diagnostic and prognostic markers and treatment strate-
gies [3-5]. In latter years real-time quantitative (RQ-)
PCR has become established as the gold standard for
accurate, sensitive and rapid quantification of gene
expression [6,7]. In comparison to alternative methods
such as Northern blotting and Ribonuclease Protection
Assays (RPA), RQ-PCR has been universally adopted as
the transcriptomic method of choice due to its superior-
ity with regard to speed, sensitivity, reproducibility and
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mercially available.
To accurately quantify an mRNA target by RQ-PCR,
samples are assayed during the exponential phase of the
PCR reaction during which the amount of target is
assumed to double with each cycle of PCR without bias
due to limiting reagents. Analysis of cycle threshold
(Ct), the cycle number at which signals are detected
above background, can be used to estimate gene expres-
sion levels by relating Ct values either to a standard
curve (absolute quantification) or to a control gene
(relative quantification). The latter method requires the
generation of standard curves of known copy number
for each target and so is limited due to logistical issues
associated with the generation of standards in studies of
multiple gene targets. Relative quantification is the most
widely adopted approach and as the name suggests,
quantification of gene expression is based on the analy-
sis of a target gene whose expression is normalised rela-
tive to the expression of a control gene. Central to the
reliable determination of gene expression is the choice
of control gene with which to normalise real-time data
from target genes. Normalisation can be achieved using
endogenous or exogenous controls; however the use of
endogenous control (EC) genes is the most widely
adopted approach as it excludes variation associated
with differences in amounts of template RNA. Vandes-
tompele et al 2002 described a normalisation method
whereby geometrical averaging of multiple EC genes
improved accuracy [8]. This approach has been adopted
to reliably measure levels of gene expression in many
studies in different tissue types including breast [9-11],
lung [12], kidney [13], brain [14] and liver [15].
An ideal EC gene (or genes) should be stably
expressed and unaffected by parameters such as disease
status and in the case of CRC, should remain unaffected
by whether a tissue was derived from normal, adenoma
or carcinoma lesions. Traditionally GAPDH (glyceralde-
hyde phosphate dehydrogenase) has been widely used to
normalise RQ-PCR data. A common feature of earlier
studies was that the stability of reference gene expres-
sion between different sample types was assumed with
little consideration paid to validation of these EC genes
as suitable normalisers. More recent studies have
brought into question the stability of commonly used
EC genes such as GAPDH on the basis that gene expres-
sion levels have been found to vary in response to treat-
ment or as a result of physiological, pathological or
experimental changes. For example, alteration in oxygen
tension and hypoxia were found to be associated with
wide variation in GAPDH, B-ACTIN and CYCLOPHILIN
expression [16]. In addition, GAPDH expression was
f o u n dt ob es t r o n g l yu n r e g u l ated in diabetic patients
and down-regulated in response to the administration of
bisphosphonate compounds in the treatment of meta-
static breast cancer [17]. Other evidence indicates that
neoplastic growth can affect EC expression levels [18].
Goidin et al [19] found differences in the expression of
GAPDH and B-ACTIN in two sub-populations of mela-
noma cells derived from a tumour in a single patient.
Treatment agents such as dexamethasone, deprenyl and
isatin also affect EC gene expression [20,21]. Schmittgen
et al [22] reported increased expression of GAPDH,
B2M, 18S rRNA and b-ACTIN in fibroblasts after the
addition of serum: evidence of the effect of experimental
conditions on EC expression. These findings were
further supported by Wu et al [23] in their investigation
of the effect of different skin irritants on GAPDH and
PolyA+ RNA expression. GAPDH was found to be
involved in age-induced apoptosis in mature cerebellar
cells [24] and also as a tRNA binding protein present in
the nuclei of HeLa cells [25].
As the use of unreliable ECs can result in inaccurate
results, the identification of the most reliable gene or set
of genes at the outset of an investigation is critical.
Thus far, a pervasive stably expressed gene (or genes)
has yet to be identified across all tissue types [26,27].
This would indicate that the identification of robust ECs
at the outset of transcriptomic analysis would yield
more reliable and meaningful RQ-PCR data.
The aim of this study was to evaluate a panel of thir-
teen candidate EC genes from which to identify the
most stably expressed gene (or genes) to normalise RQ-
PCR data derived from primary colorectal tumour and
tumour associated normal (TAN) tissue. Six of the can-
didate EC genes were selected from the literature and
represent the most frequently studied reference genes in
cancer including, but not limited to, colorectal cancer.
Each gene was previously reported as being constitu-
tively expressed in various tissues. These EC genes
included B2M (beta-2-microglogulin) [5], HPRT (hypox-
anthine guanine phosphoribosyl transferase 1) [3,28],
GAPDH [29], ACTB (beta-actin) [30], PPIA (peptidyl-
prolyl isomerise A) [9] and MRPL19 (mitochondrial ribo-
somal protein L19) [9]. The remaining seven genes
included HCRT, SLC25A23, DTX3, APOC4, RTDR1,
KRTAP12-3, and CHRNB4. The latter candidates were
selected from an unpublished whole genome microarray
dataset of 20 human tumour specimens and represented
the most stably expressed probes with a fold-change of
1.0-1.2, (p < 0.05). Expression of CXCL12 [31], FABP1
[32], MUC2 [33] and PDCD4 genes were chosen as tar-
gets against which to measure the effects of candidate
EC expression on the basis of their previously identified
roles in tumourigenesis. In addition to its tumour sup-
pressor properties, PDCD4 [34] also has diagnostic and
prognostic utility and represents a promising target for
anti-cancer therapy.
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Range of Expression of Candidate EC Genes
Ar a n g eo fC t values was observed across the candidate
EC genes in tumour and TAN tissue from CRC patients
as indicated in table 1. Only samples with a standard
deviation < 0.3 from the mean Ct of the triplicates were
included for further analysis. The expression of RTDR1,
HCRT, APOC4 and KRTAP12-3 could not be deter-
mined in all 64 tissue samples, resultantly these candi-
dates were excluded from further analysis.
Mean Ct values for the remaining genes ranged from
1 9 . 4 8( ±0 . 1 4s . e . m )f o rB2M to 32.30 (± 0.19 s.e.m) for
CHRNB4. B2M displayed the narrowest range of Ct
values between 17.5 and 21.5 (mean 19.5 ± 0.14 s.e.m,
range of 4.04) followed by PPIA and MRPL19,w h i l e
ACTB had the widest range of Ct values between 33.8
and 21.1. The genes broadly fell into three categories,
those least abundant genes with mean Ct values of 27-
32 (SLC25A23, MRPL19, DTX3 and CHRNB4), moder-
ately abundant genes with mean Ct values of 22-26
(HPRT and ACTB) and the most abundant highly
expressed genes with mean Ct values of 19-21 (B2M,
PPIA and GAPDH) Table 2.
Identification of Optimal EC genes
Scaled expression levels across the remaining nine can-
didate ECs analysed (figure 1) indicated within-gene dif-
ferences in expression between tumour and normal
tissue groups in both SLC25A23 (p = 0.040) and
CHRNB4 (P = 0.002) but not in the remaining genes (p
> 0.05), (figure 2A). Therefore, SLC25A23 and CHRNB4
genes were excluded from further analysis. Significant
differences in variance of EC expression were identified
using Levene’s test (p < 0.001, figure 2B). These findings
necessitated further evaluation of each candidate EC
gene prior to their possible use to accurately quantitate
gene expression levels of the target genes CXCL12,
FABP1, MUC2 and PDCD4.
The stability of candidate EC genes was analysed using
geNorm [8] and NormFinder [35] programmes. Stability
was further evaluated using qBasePlus [8,36], a commer-
cially available RQ-PCR data mining package. These
programmes were used to calculate amplification effi-
ciency-corrected relative quantities from raw fluores-
cence data. The ranking of candidate EC genes as
determined by each of these programmes is illustrated
in Table 3. In the case of GeNorm the variable V indi-
cating the pairwise variation (Vn/Vn+1) between two
sequential normalisation factors (NFn/NFn+1) indicated
that three EC genes was the optimal number of genes
for accurate normalisation (figure 2), however, target
genes expression did not differ significantly if two rather
than three EC genes were used (figure 3). Use of all
three programmes confirmed that B2M and PPIA was
the best combination of genes for normalising RQ-PCR
data in CRC tissues (table 3). The Equivalence test [37]
was used to examine the expression of candidate ECs.
All genes were equivalently expressed between the nor-
mal and tumour colorectal tissues using a fold cut-off of
2 (figure 4).
Association between EC genes and target genes
There was a significant effect of the expression of the
candidate EC genes on relative expression of CXCL12 (p
< 0.001), FABP1 (p < 0.001), MUC2 (p < 0.001) and
PDCD4 (p < 0.001) (figure 5A and 5B). Moreover, a sig-
nificant effect of the choice of EC with regard to the
estimation of error (figure 5C) was also detected. These
findings were further confirmed for each EC gene
Table 1 Clinico-pathological patient data for tumour and
tumour associated normal colorectal tissues
Clinicopathological Variable Number of Patients N = 42
Gender
Males 29
Females 13
Mean Age (SD) 66.5 (12.84)
Tumour Location
Colon 12
Rectum 30
Tumour Diameter (mm)
<10 11
10-15 15
>15 17
Tumour Thickness (mm)
<30 15
30-40 12
>40 15
Distant Metastasis
M0 36
M1 6
Nodal Status
N0 22
N1 11
N2 9
UICC Stage
Stage 0 6
Stage I 10
Stage II 10
Stage III 11
Stage IV 5
Tumour Differentiation
Well 12
Moderate 24
Poor 6
Mucin Secretion
Mucinous 8
Non-mucinous 34
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tests (Additional files 1). The combined use of B2M and
PPIA significantly reduced the magnitude of error in
comparison to the use of either gene individually for
both CXCL12 and PDCD4 expression. The addition of a
third EC gene (MRPL19)t ot h eB2M/PPIA combination
did not result in any further improvement of the estima-
tion of error (figure 3C).
Non-normalised expression levels of target genes
To assess whether normalisation was necessary in a
large cohort such as this in which the biological effect
of the target genes is already established, we compared
the expression of the four target genes in tumour vs.
normal tissues using non-normalised cycle threshold
(Ct) values in the entire sample set (n = 64) and in a
sub-set of randomly selected 10 normal and 10 tumour
t i s s u e s( n=2 0 ) .T h i sa n a l y s i ss h o w e dd o w n - r e g u l a t e d
target gene (CXCL12, FABP1, MUC2 and PDCD4)
expression in tumour compared to normal tissues (fig-
ure 6), in keeping with their documented tumour sup-
pressor functions, when using the larger set of samples.
The unchanged target gene expression levels in the
large cohort could be explained by the fact that in larger
sample sizes the biological milieu may diminish subtle
variations in individual samples. In contrast, when the
smaller sample size was used, no significant differences
in target gene expression were observed. Furthermore
the expression levels of PDCD4 appeared slightly higher
in tumours than in normal tissues. When the same sub-
set of 20 samples were normalised with PPIA/B2M,
significant differences in target gene expression were
observed.
Discussion
Since its introduction in 1996 [38] many methods have
been developed for the analysis real-time quantitative
PCR data. Relative quantification has come to the fore
as the method of choice due to its superior flexibility
and reduction in inherent variation associated with sam-
ple preparation. Prior to the availability of high-through-
put realtime PCR instrumentation, a handful of genes
were commonly used to normalise real-time data. Major
technological advances enabling high throughput analy-
sis of both samples and target genes have enabled inves-
tigation and validation of putative EC genes prior to
their use to normalise target gene expression. It is now
accepted that the use of more than one gene to normal-
ise RQ data improves experimental accuracy compared
to the use of a single EC gene [8,35,38]
In their study of EC gene expression in breast and
colon cancer tissues Tricarico et al [39] illustrated sig-
nificant variation in the expression levels of 10 com-
monly used housekeeping genes including 18S rRNA,
both between individuals and between biopsies taken
from the same patient. They concluded that normalisa-
tion to a single EC gene was inappropriate for human
tissue samples. Moreover, Vandesompele et al identified
errors of up to 6.5 fold when a single EC gene was used
in comparison to the use of multiple genes for data nor-
malisation [8] thereby clearly indicating the potential for
Table 2 Cycle threshold (Ct) values of candidate EC genes and PCDC4 in colorectal tissues
EC Gene Ct Range Ct Min Ct Max Mean Ct ± s.e.m Standard deviation (SD)
B2M 4.03 17.47 21.51 19.48 ± 0.14 1.04
PPIA 4.13 17.78 21.91 19.90 ± 0.14 1.06
GAPDH 5.80 18.51 24.32 21.00 ± 0.17 1.29
ACTB 12.74 21.08 33.32 25.14 ± 0.34 2.61
HPRT 8.54 22.74 31.28 26.68 ± 0.25 1.89
DTX3 6.6 24.95 31.56 28.62 ±0.17 1.37
SLC25A23 7.26 24.48 31.74 27.36 ±0.19 1.54
CHRNB4 9.40 27.99 37.38 32.30 ±0.19 2.15
RTDR1 - 30.59 UD 35.82 ±0.36 2.15
HCRT - 33.96 UD 38.46 ±0.29 1.67
APOC4 - UD UD - -
KRTAP12-3 - 33.16 UD 36.95 ±0.19 1.46
MRPL19 4.10 26.70 30.80 28.62 ± 0.13 0.98
CXCL12 13.54 21.85 35.39 25.77 ± 0.32 2.61
FABP1 15.57 16.61 32.19 20.83 ± 0.40 3.24
MUC2 17.71 17.62 35.33 22.43 ± 0.53 4.16
PDCD4 11.92 21.35 33.27 24.56 ± 0.32 2.59
B2M and PPIA were the most abundantly expressed genes, having the lowest mean Ct values while MRPL19 was the least abundantly expressed gene with
average Ct values > 26. Both B2M and PPIA had the lowest range in their Ct values.
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choice of EC genes.
Many analytical programmes for relative quantification
have been developed, certain of which enable the identi-
fication of EC genes from a study population [37,40,41].
In the present study the stability of expression of candi-
date EC genes was determined using a pair-wise com-
parison model: geNorm [8] and an MS Excel ANOVA
based model, NormFinder [35]. No effect of disease sta-
tus EC gene expression was identified in colorectal tis-
sue. Since both geNorm and NormFinder are based on
the assumption that candidate genes are not differen-
tially expressed between samples, this was an important
first step prior to their continued use [9,10].
In this study GeNorm was used to identify the most
stably expressed EC genes from our panel of candidates
and also provided a measure of the optimal number of
EC genes. B2M and PPIA were identified as the most
stable pairing. In order to achieve a pair-wise variation
value (V) below the cut-off of 0.15 additional genes
should theoretically be used; however this cut-off point
is not absolute [14] and may not always be achievable
[42]. No significant difference in target gene expression
was observed when the top three most stable EC genes
identified by geNorm were used confirming that using
of a pair of genes may be more practicable given cost,
work load and sample availability considerations.
NormFinder was designed to identify EC genes with
the lowest stability values; these values are calculated
based on intra- and inter-group variation. In this study
NormFinder was used to define the best combination of
genes using tumour and normal as group identifiers in
Figure 1 Scaled expression levels and variation of each candidate EC gene.( A )L o g1 0o fc y c l et h r e s h o l do fc a n d i d a t eE Cg e n e sACTB,
B2M, GAPDH, HPRT, MRPL19, SLC25A23, DTX3, CHRNB4 and PPIA in tumour and normal colorectal tissues. Boxplot shows interquartile range box,
median, range whiskers and outliers (*). Within gene, differences were found in expression between tissue groups in both SLC25A23 (p = 0.040)
and CHRNB4 (p = 0.002) but not the other genes (p > 0.05) (ANOVA). (B) Variation associated with EC gene expression. There was a significant
difference in variation associated with gene expression (p < 0.001) with ACTB, GAPDH and HPRT showing greater variation than B2M, MRPL19 or
PPIA. DTX3, CHRNB4 and SLC25A23 showed the least variations (Levene’s test).
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stable gene using these criteria; however B2M and PPIA
were highlighted as the best combination of genes with
even lower stability value compared to MRPL19 alone.
QBasePlus real-time PCR data manager programme was
developed based on geNorm and qBase [36] algorithms.
QBasePlus was used to confirm our selection of the
B2M and PPIA pairing as the best combination of ECs
in colorectal tissue.
Equivalence testing was developed in biostatistics to
address the situation where the aim is not to show the
difference between groups, but rather to establish that
two methods are equal to one another. In equivalence
testing, the null hypothesis is that the two groups are
not equivalent to one another, and hence rejection of
the null indicates that the two groups are equivalent.
Therefore, as stated by Haller et al,t h e r ei sar i s ko f
accepting non-differentially expressed genes as suitable
Figure 2 Analysis of candidate EC genes using geNorm. (A): Average expression stability values of eligible EC genes. Expression stability
of the control genes as calculated by geNorm. Stability value M is based on the average pair-wise variation between all genes. The least stable
gene with highest M value was excluded and M value recalculated till end up with the most stable pair. (B): Determination of optimal
number of control genes for normalisation. The GeNorm programme calculates a normalisation factor (NF) which is used to determine the
optimal number of EC genes required for accurate normalisation. This factor is calculated using the variable V as the pairwise variation (Vn/Vn +
1) between two sequential NFs (NFn and NFn + 1). To meet the recommended cut off V-value which is the point at which it is unnecessary to
include additional genes in a normalisation strategy. The recommended limit for V value is 0.15 but it is not always achievable. In this instance,
the GeNorm output file indicated that the optimal number of genes required for normalisation was three.
Kheirelseid et al. BMC Molecular Biology 2010, 11:12
http://www.biomedcentral.com/1471-2199/11/12
Page 6 of 13Figure 3 Relative quantity of CXCL12, FABP1, MUC2 and PDCD4 in colorectal tissue. Error bars indicate 95% confidence intervals. No
significant differences in the relative quantities of target genes were found using a combination of PPIA and B2M (PB) genes in comparison to
the use of combination of PPIA, B2M and MRPL19 (PBM) EC genes (ANOVA).
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Page 7 of 13controls although they are not equivalently expressed
[43]. Equivalence of expression between tumour and
normal colorectal tissue was confirmed for all candidate
EC genes using the equivalence test and a fold cut-off of
2. DTX3, B2M, MRPL19 and PPIA showed the mini-
mum of variability in the confidence interval hence can
be used for normalisation.
In their study to identify EC genes to monitor entero-
cyte differentiation and to compare normal and adeno-
carcinoma of the colon from microarray data,
Dydensborg et al [5] recommended RPLP0 for
normalising gene quantification in human intestinal
epithelial cells and B2M for studying gene expression in
human colon cancer. In addition, Blanquicett et al [44]
analysed the extent of variability in gene expression
between tumour and normal colorectal and liver tissues
using two-tailed T tests. They showed that 18S, S9 and
GUS were the least variable genes in normal and meta-
static liver specimens and were also appropriate for nor-
mal and tumour colorectal tissues. In the present study,
we confirmed that more than one EC gene is required
for optimal normalisation in colorectal tissue. We used
Figure 4 Equivalence test for candidate control genes in colorectal tissue. Differences in logarithmic expression levels between tumour and
normal tissues (●) are indicated. The upper and lower bars of each line indicate the upper and lower limits of the symmetrical confidence
intervals, respectively. The deviation area (-1, 1) for a fold change of 2 or less is plotted as a continuous line while the deviation area of (-1.58,
1.58) for a fold change of 3 is plotted as a dotted line.
Table 3 Ranking and best combination of EC genes as determined by geNorm, NormFinder and qBasePlus.
Rank GeNorm NormFinder qBaseplus
Gene Stability (M) Gene Stability (M) Gene CV value
1 GAPDH 1.477 MRPL19 0.008 GAPDH 0.555
2 MRPL19 1.467 B2M 0.015 PPIA 0.659
3 PPIA 1.535 HPRT 0.016 HPRT 0.775
4 B2M 1.636 PPIA 0.017 MRPL19 0.914
5 HPRT 1.813 GAPDH 0.018 B2M 0.923
6 DTX3 2.251 DTX3 0.020 ACTB 0.957
7 ACTB 2.454 ACTB 0.026 DTX3 5.829
Best Combination B2M/PPIA 1.005 B2M/PPIA 0.007 B2M/PPIA 0.460
For GeNorm, lower stability values (M) indicate greater stability. In the case of NormFinder, stability is calculated from inter- and intra-group variation. By
grouping the tissues into tumour and normal the best combination of genes was identified. For geNorm stability was based on the estimation of pair-wise
variation. QBasePlus through its components, geNorm and qBase, identified coefficient of variation (CV) and stability (M) values and thereby the best
combination of genes for normalisation only when more than one gene is used.
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Page 8 of 13Figure 5 Relative quantity of target gene expression in colorectal tissues relative to each EC gene and to the geometric mean of the
combined use of PPIA and B2M (PB). (A) Target gene expression in tumour versus normal using either individual candidate EC genes or the
PB combination. (B) Significant differences in relative gene expression values as determined using ANOVA to compare mean expression levels
across all tissues using either individual EC genes or PB in combination. (C) One way ANOVA indicating a reduction in the magnitude of error
when the PB combination was used to normalise expression of CXCL12 (p < 0.001) and PDCD4 (p < 0.001) in comparison to the use of
individual EC genes. See Table 1 Additional files for Post Hoc tests. Error bars indicate 95% confidence intervals.
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Page 9 of 13clinico-pathologically diverse tissues to systematically
evaluate normalisation of gene expression data in color-
ectal tissues. We also conducted equivalence testing to
confirm the equality of expression of each EC gene.
Thereby, the risks of incorrect rejection (type 1 error)
and of false negativity (type 2 error) were minimised.
As stated above significant differences in target gene
expression were noticed when using each of the EC
genes and the combination of PPIA and B2M.M o r e -
over, significant effect of EC on the magnitude of error
associated with estimation of target gene expression was
also determined in this study (figure 6). Our results
were further confirmed by post hoc testing of individual
levels of EC gene expression (Additional files 1). Reduc-
tion in the magnitude of error achieved using the com-
bination of PPIA and B2M in comparison to using
individual EC genes alone, further indicates that using
two EC genes to normalise real-time data achieves
greater accuracy in the determination of gene expression
levels.
Conclusions
The findings reported in this study confirm that use of
two EC genes to normalise RQ-PCR data resulted in
superior accuracy in the quantification of gene expres-
sion in colorectal tissue. The combined use of B2M and
PPIA was validated as the optimal pair of EC genes with
which to estimate the expression of all four target genes
in colorectal cancer tissue. Although these ECs may not
be ideal in other tissue types, the approach described
herein could serve as a template to identify valid ECs in
other tissue types.
Methods
Tissue Samples
A study group of 64 biopsies of human colon tissue
samples was gathered from consenting patients at the
time of primary curative surgical resection at Galway
University Hospital, Ireland. The cohort comprised of
30 colorectal tumour specimens and 34 and tumour-
associated normal (TAN) tissues. Following excision, all
samples were subject to histopathological review prior
immediate snap-freezing in liquid nitrogen and archival
at -80°C until further use. Concomitant clinicopathologi-
cal data on patients and specimens was obtained from
the Department of Surgery Biobank, NUI Galway as
detailed in Table 4. Ethical approval for this study was
granted by the Clinical Research Ethics Committee, Gal-
way University Hospitals.
RNA Extraction and Analysis
Tissue samples (50-100 mg) were homogenised using a
hand-held homogenizer (Polytron® PT1600E, Kinematica
AG, Littau-Luzem, Switzerland) in 1-2 ml of QIAzol
reagent (Qiagen, Crawley, UK). To minimise variation in
sample processing, tumour and TAN samples were
homogenised separately, but on the same day. RNA was
extracted as previously described (Davoren et al)u s i n g
the RNeasy® Plus Mini Kit and RNeasy MinElute®
cleanup kit (Qiagen, Crawley, UK) according to the
manufacturer’s instructions. Briefly, large (> 200 nt) and
Figure 6 Non-normalised cycle threshold (Ct)o fCXCL12, FABP1, MUC2 and PDCD4 in colorectal tissue. Using this approach, the
expression of each gene appears to be down-regulated in tumours compared to normal tissues in the large cohort of patients (30 tumour and
34 normal tissue specimens), similar to previous published reports of reduced expression in colorectal tumours. No significant differences were
noted in expression levels of target genes when using the small cohort of patients (10 tumour and 10 normal tissue specimens) (2-sample t-
test). This confirms the effect of sample size on findings when using non-normalised Ct values and therefore the importance of normalisation
especially in such type of studies
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For this study, only large RNA was utilised for further
analysis. RNA was eluted in 60 μl volumes and stored at
-80°C.
RNA concentration and purity was assessed in dupli-
cate samples using a using a NanoDrop™ ND-1000 Spec-
trophotometer (Thermo Fisher Scientific, USA). RNA
integrity was evaluated using the RNA 6000 Nano Chip
Kit (Series II) and the Agilent 2100 Bioanalyzer System
(Agilent technologies, Palo Alto, CA, USA). An RNA
integrity number (RIN) was generated for each sample
using the Agilent 2100 Expert Software (Version
B.02.03) based on the ratio of ribosomal bands and also
the presence or absence of degradation products on the
electrophoretic and gel-like images. A threshold value of
RIN ≥ 7 was applied and RNA purity was verified by an
average A260/A280 ratio of 1.98 (range 1.97-2.01) and
A260/A230 ration of 1.7 (range 1.5-1.83).
Candidate Endogenous Control Genes
Based on literature search six commonly used candidate
endogenous control genes were selected for analysis:
ACTB, GAPDH, HPRT, B2M, PPIA and MRPL19.A n
additional panel of seven genes: HCRT, SLC25A23,
D T X 3 ,A P O C 4 ,R T D R 1 ,K R T A P 1 2 - 3a n dC H R N B 4 ,w a s
also selected for analysis (Table 2). To our knowledge
all genes have independent cellular functions and were
assumed not to be co-regulated.
cDNA Synthesis and RQ-PCR
First strand cDNA was synthesised using Superscript™
III reverse transcriptase (Invitrogen Life technologies,
Paisley, UK) and random primers (N9; 1 μg, MWG Bio-
tech, AG, Ebersberg, Germany). Negative control sam-
ples were included in each set of reactions. Reactions
were incubated at 25°C for 5 minutes followed by 50°C
for 1 hour and final denaturation at 72°C for 15
minutes. Samples were subsequently diluted to 50 μLi n
nuclease-free water and stored at -20°C. The expression
of each EC gene was analysed by RQ-PCR using Taq-
Man® gene expression assays using a 7900HT instru-
ment (Applied Biosystems, Foster city, USA). All
reactions were performed in 20 μL reactions, in tripli-
cate within the same PCR run. Negative controls were
included for each gene target under assay. On each
plate, an interassay control was included to account for
any variations between runs. For each well 2 μlo f
cDNA from each sample was added to 18 μlo fP C R
reaction mix which consisted of 10× TaqMan® universal
master mix, No AmpErase UNG, 7× nuclease free water
a n d1 ×g e n ee x p r e s s i o na s s a yp r i m e r - p r o b em i x
(Applied Biosystems, Foster city, USA). The PCR reac-
tions were initiated with a 10 minute incubation at 95°C
followed by 40 cycles of 95°C for 15 seconds and 60°C
for 60 seconds, in accordance with the manufacturer’s
recommendations.
PCR Amplification Efficiency
Amplification efficiencies for each EC gene assay were
calculated applying the formula E = (10-1/slope - 1) ×
100, using the slope of the plot of Ct versus log input of
cDNA (10-fold dilution series). A threshold of 10%
above and below 100% efficiency was applied. PCR
amplification efficiency for each candidate EC gene is
shown in table 2.
Data Analysis
Cycle threshold (Ct) is defined as the PCR cycle number
at which the fluorescence generated from amplification
of the target gene within a sample increases to a thresh-
old value of 10 times the standard deviation of the base
line emission and is inversely proportionate to the start-
ing amount of the target cDNA. QBasePlus was used for
calculation of PDCD4 expression relative to each of the
Table 4 Candidate endogenous control (EC) genes and their PCR amplification efficiencies (E)
EC Function Chromosomal Location Amplicon Size (bp) Assay Identifier* E (%)
B2M Defence/immunity 15q21-22.2 64 Hs00187842_m1 101.8
GAPDH Oxidoreductase, dehydrogenase 12p13 122 Hs99999905_m1 99.8
PPIA Isomerase 7p13 98 Hs99999904_m1 96.6
HPRT Glycosyl transferase Xq26.1 100 Hs99999909_m1 97.9
MRPL19 Protein biosynthesis 2q11.1-11.2 72 Hs00608519_m1 102.2
ACTB Cytoskeletal structure 7p15-12 171 Hs99999903_m1 95.2
DTX3 Signals transduction 12q13.3 64 Hs00400987_m1 99.1
SLC25A23 Mitochondrial carrier 19p13.3 86 Hs00225469_m1 97.8
CHRNB4 Nicotinic receptor 15q24 75 Hs00609523_m1 103.6
RTDR1 Aminopeptidase transport 22q11.2 112 Hs00205353_m1 UD
HCRT Homeostatic regulator 12q21 101 Hs00533664_m1 UD
APOC4 Apo-lipoprotein 19q.2 144 Hs00155791_m1 UD
KRTAP12-3 Acetylgalactoa-minyltransferase 3q25 83 Hs01651247_s1 UD
* Applied Biosystems TaqMan® gene expression assay ID
UD: undetermined
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=( C t target gene, test sample - Ct endogenous control,
test sample) - (Ct target gene, calibrator sample - Ct
endogenous control, calibrator sample). Relative quanti-
ties were corrected for efficiency of amplification and
fold change in gene expression between groups was cal-
culated as E-ΔΔCt ± s.e.m. Where more than one endo-
genous control are used, fold change estimates were
calculated using the geometric mean of EC quantities
relative to the calibrator sample which could be the
minimum, maximum or a named sample or an average.
Stability of the EC genes expression was evaluated
with two freely available statistical models, geNorm and
NormFinder. It is further validated with qBasePlus. Sta-
tistical analysis was carried out with Minitab® 15 (Mini-
tab Ltd, Coventry, UK). Anderson-Darling normality test
was applied and parametric tests were used where
appropriate. The equivalence test was used to assess the
equivalently of expression of the candidate genes
between tumour and normal tissues. One-way ANOVA,
two-sample t-test, Levene’s test and Spearman and Pear-
son correlations were used to determine association and
comparisons between groups. P values < 0.05 were con-
sidered statistically significant.
Additional file 1: Table 1 Supplementary data. Post hoc testing of
individual levels of EC gene expression.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2199-11-
12-S1.PPT]
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